-transparent.png){kind=logo}
Because of its severe side effects, initial clinical trials of the antineoplastic compound mitoguazone (Methyl-GAG, M-G) were ceased in the middle of 1960s. One decade later pharmacokinetically guided dose schedules as well as new experimental data on the antiproliferative mechanism of action stimulated new clinical studies. First results indicated that M-G had single-agent activity against various tumors such as acute leukemia and malignant lymphoma connected with acceptable tolerance. M-G seems to be effective especially in combination with other antineoplastic drugs. Its final evaluation may be reserved to further randomized trials. Recently, the psoriasis vulgaris is expected to be an additional field of the application of M-G. In this minireview data on synthesis, preclinical pharmacology, pharmacokinetics, biochemical effects and toxicology of M-G are given. Furthermore, clinical findings on M-G concerning its pharmacokinetic behaviour, antitumor and antipsoriatic activities are described.
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
January 1983,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
August 1968,
Journal of pharmaceutical sciences,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
May 1963,
Journal of medicinal chemistry,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
July 1963,
Journal of medicinal chemistry,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
July 1966,
Journal of medicinal chemistry,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
September 1968,
Acta virologica,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
September 1963,
Cancer research,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
February 1983,
The Journal of pathology,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
November 1964,
Journal of medicinal chemistry,
H Hoffmann, and
W Gutsche, and
R Amlacher, and
W Schulze, and
W Werner, and
H Lenk, and
W Wohlrab, and
E Haupt
January 1990,
European journal of cancer (Oxford, England : 1990),
